Results 251 to 260 of about 668,836 (354)

Tailored Porous Bimetallic Nanozyme Platform for Full‐Cycle Therapeutics of Intestinal Ischemia/Reperfusion

open access: yesAdvanced Science, EarlyView.
ABSTRACT Intestinal ischemia/reperfusion (I/R) injury presents a biphasic pathology: an acute oxidative‐inflammatory phase leading to organ failure, and a recovery phase marked by mucosal dysfunction and bacterial translocation. The developed MPB@TA‐Cu‐Ma nanocomposite functions as a dual‐phase therapeutic platform with significant efficacy. It rapidly
Chenghao Qiu   +15 more
wiley   +1 more source

Leveraging Macrophage Metabolic Reprogramming for Enhanced Anti‐Tumor Immunity

open access: yesAdvanced Science, EarlyView.
Tumor‐associated macrophages (TAMs) are key regulators of the tumor microenvironment (TME), with their metabolic states playing a critical role in tumor progression or regression. This review summarizes current understanding of TAM metabolic plasticity alongside cutting‐edge bioengineering innovations, outlining a roadmap for transforming the ...
Zhiyun Liu   +8 more
wiley   +1 more source

Supplementary Figure S3 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies

open access: gold
Ekta Patel   +29 more
openalex   +1 more source

Effect of interleukin 12 (IL-12) on embryonic development and yolk sac vascularisation

open access: bronze, 2014
Mehtap Nisari   +4 more
openalex   +2 more sources

Lymphoid‐Tissue‐on‐Chip Recapitulates Human Antibody Responses In Vitro

open access: yesAdvanced Science, EarlyView.
The presented lymphoid‐tissue‐on‐chip system allows culture of primary human tonsil cells at organotypic high density under perfusion for up to 4 weeks, emulates immune response to soluble vaccines and vaccination via peripheral antigen‐presenting cells and represents a useful tool to assess cellular interactions during homeostasis, immune responses ...
Claudia Teufel   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy